Консенсусные рекомендации по управлению множественным склерозом в Австралии и Новой Зеландии: часть 2.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shipley Jessica, Beharry James, Yeh Wei, Seery Nabil, Foong Yi Chao, Ayton Darshini, Siriratnam Pakeeran, Tan Tracie, Beadnall Heidi, Barton Joshua, Bridge Francesca, Wesselingh Robb, Taylor Lisa, Rath Louise, Haartsen Jodi, Gadi Mohammad, Nesbitt Cassie, Zhong Michael, Cushing Victoria, McKay Fiona, Morahan Julia, Trewin Benjamin Peter, Roos Izanne, Marriott Mark, Nguyen Ai-Lan, Downey Emma, Crosby Joanne, Bosco Julian, Taylor Jennifer, Giles Lauren, John Nevin, Butler Ernest, van der Walt Anneke, Butzkueven Helmut, Blum Stefan, Simpson Marion, Slee Mark, Ramanathan Sudarshini, Hardy Todd, Macdonell Richard A L, Buzzard Katherine, Mason Deborah F, Lechner-Scott Jeannette, Kilpatrick Trevor J, Kalincik Tomas, Taylor Bruce V, Broadley Simon A, Reddel Stephen, Johnson Douglas, Monif Mastura, MS Interest Group, Australian and New Zealand Association of Neurologists
Аннотация
Оригинал публикации
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2.
INTRODUCTION: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system with rapidly evolving treatment options and strategies. An iterative modified Delphi process was used to develop 80 consensus recommendations for the management of MS in Australia and New Zealand. Part 1 of these guidelines includes recommendations related to selection of initial disease-modifying therapy (DMT) for MS, assessments before commencing DMT, monitoring disease activity on DMT, switching DMT, and discontinuing DMT.
MAIN RECOMMENDATIONS: This article, Part 2, covers recommendations related to risk mitigation during treatment with DMT, managing DMT in special situations (including pregnancy, postpartum, breastfeeding, active infection including COVID-19, and malignancy), general lifestyle measures for MS, acute MS relapses, and symptomatic treatments.
CHANGES IN MANAGEMENT AS A RESULT OF THE GUIDELINES: Together with Part 1, this consensus statement provides practical guidance for clinicians involved in the care of adults (≥ 18 years old) with MS in Australia and New Zealand. A safe, effective and comprehensive approach to managing MS is crucial for improving long term outcomes and quality of life in individuals affected by MS.